Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue

We previously demonstrated that targeting lymphotoxin alpha (LTalpha) to the tumor evokes its immunological destruction in a syngeneic B16 melanoma model. Since treatment was associated with the induction of peritumoral tertiary lymphoid tissue, we speculated that the induced immune response was ini...

Full description

Saved in:
Bibliographic Details
Published in:Cancer immunology, immunotherapy : CII immunotherapy : CII, 2008-01, Vol.57 (1), p.85-95
Main Authors: Schrama, David, Voigt, Heike, Eggert, Andreas O, Xiang, Rong, Zhou, He, Schumacher, Ton N M, Andersen, Mads H, thor Straten, Per, Reisfeld, Ralph A, Becker, Jürgen C
Format: Article
Language:English
Subjects:
Animals
Gangliosides - immunology
Humans
Immunohistochemistry
Lymphocyte Activation - immunology
Lymphocytes, Tumor-Infiltrating
Lymphoid Tissue - cytology
Lymphoid Tissue - immunology
Lymphotoxin-alpha - immunology
Lymphotoxin-alpha - therapeutic use
Melanoma, Experimental - immunology
Melanoma, Experimental - therapy
Mice
Mice, Inbred C57BL
Mice, Knockout
Recombinant Fusion Proteins - immunology
Recombinant Fusion Proteins - therapeutic use
T-Lymphocytes - immunology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We previously demonstrated that targeting lymphotoxin alpha (LTalpha) to the tumor evokes its immunological destruction in a syngeneic B16 melanoma model. Since treatment was associated with the induction of peritumoral tertiary lymphoid tissue, we speculated that the induced immune response was initiated at the tumor site. In order to directly test this notion, we analyzed the efficacy of tumor targeted LTalpha in LTalpha knock-out (LTalpha(-/-)) mice which lack peripheral lymph nodes. To this end, we demonstrate that tumor-targeted LTalpha mediates the induction of specific T-cell responses even in the absence of secondary lymphoid organs. In addition, this effect is accompanied by the initiation of tertiary lymphoid tissue at the tumor site in which B and T lymphocytes are compartmentalized in defined areas and which harbor expanded numbers of tumor specific T cells as demonstrated by in situ TRP-2/K(b) tetramer staining. Mechanistically, targeted LTalpha therapy seems to induce changes at the tumor site which allows a coordinated interaction of immune competent cells triggering the induction of tertiary lymphoid tissue. Thus, our data demonstrate that targeted LTalpha promotes an accelerated immune response by enabling the priming of T cells at the tumor site.
ISSN:0340-7004